Abstract: Peritoneal mesothelioma is a rare tumor typically presenting with ascites and associated with occupational asbestos exposure with a latency period of 20-40 years. Intensive multi-modality approach combining cytoreductive surgery, intraperitoneal chemotherapy and possibly radiotherapy can be considered, but otherwise the prognosis is rather poor. Palliative chemotherapy may be an option in these rare cases. However, no approved systemic treatment exists for peritoneal mesothelioma. We present here a patient with peritoneal mesothelioma who was treated with the combination of pemetrexed with cisplatin shortly after the failure of hyperthermic intraperitoneal chemotherapy. The patient experienced durable partial response to the treatment, resolution of ascites, and returned to his normal daily life activities. With the exception of palliative chemotherapy in case of patients in good condition, therapeutic options in patients with peritoneal mesothelioma are currently very limited. The combination of pemetrexed and cisplatin can lead to long-term control in selected patients.
Introduction
Malignant peritoneal mesothelioma is a rare tumor with a yearly incidence about 1-2 cases per million in Europe while the incidence of pleural mesothelioma is three to 30-fold higher in different countries, depending on the level of industrialization [1] . Mesothelioma typically affects older men after 50 years of age, with a latency period of 20-40 years between asbestos exposure and development of disease [2, 3] . Epitheloid histology has consistently been associated with a better prognosis [4] , however, the prognosis is rather poor. Intensive multimodality approach comprising of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers the best long-term outcome [5] [6] [7] , but this treatment is feasible only in the minority of patients.
For patients not suitable for curative resection, median overall survival was reported to range between 6 and 9 months [8] . Palliative systemic intravenous chemotherapy remains the only option, but this tumor is, in general, considered chemoresistant. As there is no chemotherapeutic agent that has demonstrated a consistent survival advantage in peritoneal mesothelioma, either alone or in combination, and due to inadequate number of patients who could be enrolled in prospective trials, there currently exists no approved treatment for peritoneal mesothelioma and the therapeutic strategy generally follows guidelines for pleural mesothelioma [9] . There is no generally accepted strategy for patients failing HIPEC.
Antifolate agents were among the first cytotoxic drugs to show activity in mesothelioma. The first antifolate agent to show efficacy was high-dose methotrexate with a median survival of 11 months [10] . In 2004, pemetrexed was approved worldwide to be used in combination with cisplatin for the treatment of malignant pleural mesothelioma in patients with unresectable disease [11] . The combination of cisplatin with pemetrexed was associated with a response rate of 41.3%, median time to progression of 5.7 months and median overall survival of 12.1 months, and the treatment has become the standard first-line therapy in mesothelioma. The activity of pemetrexedbased chemotherapy in peritoneal mesothelioma has not been prospectively investigated.
We present here an exceptional case of a patient with peritoneal mesothelioma with a durable partial response to the systemic treatment with chemotherapy and review literature on this topic.
Case report
A 51-year-old man, with history of arterial hypertension, presented in April 2013 with massive ascites that was refractory to conservative treatment. The computed tomography (CT) scans revealed only ascites and laboratory results were otherwise normal. Because laboratory tests, repeated negative cytology of ascites and CT scans were inconclusive, the patient was referred for surgery and on October 10, 2013 underwent explorative laparotomy. The surgery revealed multiple diffuse whitish lesions 1-5 mm in size on peritoneum and omentum. Unexpectedly, on histological examination moderately to poorly differentiated epitheloid malignant mesothelioma of peritoneum was diagnosed. Because of diagnosis of peritoneal mesothelioma, the patient was scheduled for cytoreductive surgery and on January 8, 2014 underwent (outside of our center) omentectomy and debulking followed by HIPEC. Due to massive tumor involvement of the peritoneum, surgical debulking was considered palliative. Follow-up CT examination in February 2014 ( Figure 1A ) demonstrated new metastatic lesions in the lung and progression of ascites. Between March and July 2014 the patient was treated with 7 cycles of systemic chemotherapy using regimen combining cisplatin and pemetrexed. Chemotherapy was stopped because of moderate symptoms of peripheral neuropathy. On CT examination in September 2014 ( Figure 1B ), partial regression of ascites and lung metastases was evident. This continues 16 months after the completion of therapy ( Figure 1C ). Neuropathy showed to be partially reversible, nevertheless mild tingling in feet remains. The patient has no other complaints.
Discussion and review of the literature
We report here a rare patient with malignant peritoneal mesothelioma, who presented with massive refractory ascites and peritoneal infiltration of unknown origin. The diagnosis of epitheloid peritoneal mesothelioma was eventually made during explorative laparotomy. Initially, the patient was treated by HIPEC, an approach reported to provide the best long-term outcome [5] [6] [7] , but in the present case the procedure was rather palliative due to advanced stage of the disease and failed to show any benefit. Because of subsequent rapid progression of ascites with a need of regular weekly paracentesis, the patient was treated with chemotherapy using the combination of cisplatin and pemetrexed. The patient completed seven cycles of chemotherapy achieving partial response on CT scan when the therapy was stopped for neurotoxicity which was later shown to be nearly fully reversible. During the course of chemotherapy, there was no need for more ascites evacuation. The patient has achieved durable partial response that continues 16 months after the completion of chemotherapy.
This case report is highly relevant to daily oncology practice. In the present case, we observed an excellent treatment response in a tumor characterized by chemoresistant behavior. Nevertheless, it has been reported that patients with peritoneal mesothelioma with epitheloid histology have better outcomes than those with either mixed or sarcomatoid histology. The patient was put at a disadvantage by the late diagnosis due to diagnostic uncertainty and repeatedly negative cytologic samples of ascites as is common in this disease [12] . The final diagnosis was ultimately made during explorative laparotomy.
It is generally recommended that patients with mesothelioma be managed by a multidisciplinary team with experience in the management of mesothelioma. Since there currently exist no approved treatments for peritoneal mesothelioma, the treatment strategy generally follows the guidelines for the more frequent pleural mesothelioma. Treatment options include cytoreductive surgery, radiotherapy and HIPEC. Multimodality treatment is appropriate only for patients medically operable with a good performance status and may ultimately result in better outcomes in such selected population. Pretreatment evaluation may be a challenge, as is the assessment of tumor response because applicability of standard response evaluation criteria in solid tumors (RECIST) is limited in pleural mesothelioma, especially with respect to the assessments of the pleural rind [13] and with peritoneal mesothelioma the situation is practically identical. Most patients have advanced disease at presentation. In case metastatic disease is excluded by CT or PET/CT, cytoreductive surgical resection is recommended for patients who are medically operable. To identify prognostic factors with regard to the extent of peritoneal carcinomatosis, peritoneal cancer index (PCI) score is used. Recently published data demonstrated that PCI remains the most important factor predicting long-term survival in patients with peritoneal carcinomatosis. A crucial role is played not only by the extent of peritoneum affected, but the involvement of certain areas of peritoneum may portend more favorable prognosis compared to areas such as 9, 10 and 11 (regions involving the small bowel), which predict a significantly worse outcomes [14] . On the other hand, for patients who are inoperable, with metastases or sarcomatoid histology, systemic chemotherapy is indicated. The patient in the present report had PCI > 20 that was associated with rapid progression after HIPEC.
Pemetrexed, [15]. Pemetrexed is currently used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Data on systemic anticancer therapy in peritoneal mesothelioma are very limited [16] [17] [18] [19] . As mentioned above, pemetrexed is registered for the treatment of malignant pleural mesothelioma [11] , and the activity of this anticancer drug in mesothelioma of other primary locations is supported mostly by retrospective data [9, [19] [20] [21] . The expanded access program (EAP) for pemetrexed that included 113 patients with peritoneal mesothelioma and indicated the efficacy of pemetrexed alone or in combination with cisplatin or carboplatin in the treatment of malignant peritoneal mesothelioma has been reported [9] . The data showed an overall response rate of 18.7%, disease control rate of 68.1% and an overall 1-year survival rate of 47.4%. The combination also had an acceptable safety profile. Another EAP conducted in the United States treating patients with pemetrexed alone or in combination with cisplatin for peritoneal mesothelioma reported the response rate of 23.9% [19] . The phase III trial of malignant pleural mesothelioma treated with cisplatin with or without pemetrexed showed response rate of 41.3% and the median overall survival of 12.1 month, but unlike the other trials, only chemotherapynaive patients were included [11] .
Given the paucity of published data on this topic, the diagnostic and therapeutic approach in the cases of peritoneal mesothelioma is determined only by expert recommendations, especially in cases of patients with rapid recurrence after prior HIPEC. A case report on the efficacy of the pemetrexed/cisplatin regimen combined with regional hyperthermia has been published recently [22] , but the detailed information on prior therapy is missing in the retrospective series reporting the efficacy of pemetrexed in peritoneal mesothelioma. Thus, the efficacy of pemetrexed/cisplatin combination therapy in patients failing HIPEC is currently unknown. In addition, in EAPs, most pretreated patients were given pemetrexed monotherapy rather than the combination [9, 23] . Retrospective series or case reports like the present one remain the only source of information on the management of patients with this rare disease. In contrast to some other solid tumors, there is currently no effective targeted treatment for advanced peritoneal mesothelioma, and systemic therapy has, at best, only limited role in the management of patients with metastatic peritoneal mesothelioma. As mentioned above, intensive multimodality approach comprising of cytoreductive surgery followed by intraperitoneal chemotherapy should always be attempted in cases of patients with operable diffuse malignant peritoneal mesothelioma (DMPM) because it offers a chance of long-term survival in selected cases compared with systemic therapy alone. Recently published data from an Australian center showed 5-year survival for DMPM with PCI < 10, 10-20 and > 20 were 100, 55 and 39%, respectively [24] . However, in patients failing HIPEC the therapeutic options are very limited.
The mechanism(s) of prolonged response in this particular patient remain speculative at this time. Similarly to most other cytotoxic agents, there are currently no biomarkers that would allow prediction of response to pemetrexed. While in medical oncology most attention has been historically focused so far on biomarkers associated with the properties of the tumor cell, the biomarkers assessing the host response to neoplasia could be of equal importance [25] . For example, systemic immune response indicated by increased neopterin concentrations has been associated with poor outcome across a range of neoplastic disorders [26] . This could be caused by an association of systemic immune activation evidenced by increased neopterin levels with the dysfunction of immune response [27] [28] [29] . In fact, immune response could represent an important factor in determining the efficacy of cytotoxic therapy [30] . Whether the activity of the pemetrexed/cisplatin combination in mesothelioma is also affected by the immune response remains to be determined.
In conclusion, the present case demonstrates that patients with advanced malignant peritoneal mesothelioma may experience a prolonged response to systemic chemotherapy combining cisplatin and pemetrexed even after failure of prior therapy, with a good safety profile. The combination was both active and well tolerated in a patient with peritoneal mesothelioma. There is currently no other effective treatment option which would prolong survival in patients with inoperable disease.
